Androgen Deprivation Therapy (ADT) for Men with Prostate Cancer

Article and Video CATEGORIES

Cancer Journey

ABOUT

Ramy Sedhom, MD, is a Medical Oncology Fellow at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland.

He is interested in Supportive and Palliative Care for patients across the cancer continuum - from a clinical, research, and policy perspective. Following his oncology training, he will be pursuing a clinical fellowship in Hospice and Palliative Care.

GRACE is very excited to bring you more info from our new program, Supportive Care in Cancer Treatment.

Ramy Sedhom, MD, with Johns Hopkins in Baltimore, Maryland, hosts this episode of Supportive Care in Cancer Treatment. In this video Dr. Sedhom and his guest, Dr. Tyler Stewart with the Moores Cancer Center, UC San Diego, discuss Androgen Deprivation Therapy or ADT for men with prostate cancer.

To join the conversation, visit https://cancergrace.org/forum.

To donate to GRACE, visit https://cancergrace.org/donate.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.